97 related articles for article (PubMed ID: 20193471)
1. [Recent advances on EZH2 in malignant tumors].
Li J; Fan QH
Zhonghua Bing Li Xue Za Zhi; 2009 Dec; 38(12):856-8. PubMed ID: 20193471
[No Abstract] [Full Text] [Related]
2. The Polycomb group protein Enhancer of Zeste 2: its links to DNA repair and breast cancer.
Zeidler M; Kleer CG
J Mol Histol; 2006 Sep; 37(5-7):219-23. PubMed ID: 16855786
[TBL] [Abstract][Full Text] [Related]
3. Increased expression of the polycomb group gene, EZH2, in transitional cell carcinoma of the bladder.
Raman JD; Mongan NP; Tickoo SK; Boorjian SA; Scherr DS; Gudas LJ
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8570-6. PubMed ID: 16361539
[TBL] [Abstract][Full Text] [Related]
4. Distinctive expression of the polycomb group proteins Bmi1 polycomb ring finger oncogene and enhancer of zeste homolog 2 in nonsmall cell lung cancers and their clinical and clinicopathologic significance.
Kikuchi J; Kinoshita I; Shimizu Y; Kikuchi E; Konishi J; Oizumi S; Kaga K; Matsuno Y; Nishimura M; Dosaka-Akita H
Cancer; 2010 Jun; 116(12):3015-24. PubMed ID: 20564407
[TBL] [Abstract][Full Text] [Related]
5. High expression of EZH2 is associated with tumor proliferation and prognosis in human oral squamous cell carcinomas.
Kidani K; Osaki M; Tamura T; Yamaga K; Shomori K; Ryoke K; Ito H
Oral Oncol; 2009 Jan; 45(1):39-46. PubMed ID: 18619895
[TBL] [Abstract][Full Text] [Related]
6. Enhancer of Zeste 2 as a marker of preneoplastic progression in the breast.
Ding L; Kleer CG
Cancer Res; 2006 Oct; 66(19):9352-5. PubMed ID: 17018586
[TBL] [Abstract][Full Text] [Related]
7. Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation.
Kondo Y; Shen L; Cheng AS; Ahmed S; Boumber Y; Charo C; Yamochi T; Urano T; Furukawa K; Kwabi-Addo B; Gold DL; Sekido Y; Huang TH; Issa JP
Nat Genet; 2008 Jun; 40(6):741-50. PubMed ID: 18488029
[TBL] [Abstract][Full Text] [Related]
8. Integration of estrogen and Wnt signaling circuits by the polycomb group protein EZH2 in breast cancer cells.
Shi B; Liang J; Yang X; Wang Y; Zhao Y; Wu H; Sun L; Zhang Y; Chen Y; Li R; Zhang Y; Hong M; Shang Y
Mol Cell Biol; 2007 Jul; 27(14):5105-19. PubMed ID: 17502350
[TBL] [Abstract][Full Text] [Related]
9. Context-specific regulation of NF-κB target gene expression by EZH2 in breast cancers.
Lee ST; Li Z; Wu Z; Aau M; Guan P; Karuturi RK; Liou YC; Yu Q
Mol Cell; 2011 Sep; 43(5):798-810. PubMed ID: 21884980
[TBL] [Abstract][Full Text] [Related]
10. Increased expression of EZH2, a polycomb group protein, in bladder carcinoma.
Arisan S; Buyuktuncer ED; Palavan-Unsal N; Caşkurlu T; Cakir OO; Ergenekon E
Urol Int; 2005; 75(3):252-7. PubMed ID: 16215315
[TBL] [Abstract][Full Text] [Related]
11. Importance of Ezh2 polycomb protein in tumorigenesis process interfering with the pathway of growth suppressive key elements.
Tonini T; D'Andrilli G; Fucito A; Gaspa L; Bagella L
J Cell Physiol; 2008 Feb; 214(2):295-300. PubMed ID: 17786943
[TBL] [Abstract][Full Text] [Related]
12. PRAME expression is not associated with down-regulation of retinoic acid signaling in primary acute myeloid leukemia.
Steinbach D; Pfaffendorf N; Wittig S; Gruhn B
Cancer Genet Cytogenet; 2007 Aug; 177(1):51-4. PubMed ID: 17693191
[TBL] [Abstract][Full Text] [Related]
13. High-grade neuroendocrine carcinomas of the lung highly express enhancer of zeste homolog 2, but carcinoids do not.
Findeis-Hosey JJ; Huang J; Li F; Yang Q; McMahon LA; Xu H
Hum Pathol; 2011 Jun; 42(6):867-72. PubMed ID: 21292308
[TBL] [Abstract][Full Text] [Related]
14. Expression levels of the EZH2 polycomb transcriptional repressor correlate with aggressiveness and invasive potential of bladder carcinomas.
Weikert S; Christoph F; Köllermann J; Müller M; Schrader M; Miller K; Krause H
Int J Mol Med; 2005 Aug; 16(2):349-53. PubMed ID: 16012774
[TBL] [Abstract][Full Text] [Related]
15. Activation of the enhancer of zeste homologue 2 gene by the human papillomavirus E7 oncoprotein.
Holland D; Hoppe-Seyler K; Schuller B; Lohrey C; Maroldt J; Dürst M; Hoppe-Seyler F
Cancer Res; 2008 Dec; 68(23):9964-72. PubMed ID: 19047178
[TBL] [Abstract][Full Text] [Related]
16. EZH2 silencing by RNA interference inhibits proliferation in bladder cancer cell lines.
Zhang YB; Niu HT; Chang JW; Dong GL; Ma XB
Eur J Cancer Care (Engl); 2011 Jan; 20(1):106-12. PubMed ID: 20148941
[TBL] [Abstract][Full Text] [Related]
17. Curcumin induces down-regulation of EZH2 expression through the MAPK pathway in MDA-MB-435 human breast cancer cells.
Hua WF; Fu YS; Liao YJ; Xia WJ; Chen YC; Zeng YX; Kung HF; Xie D
Eur J Pharmacol; 2010 Jul; 637(1-3):16-21. PubMed ID: 20385124
[TBL] [Abstract][Full Text] [Related]
18. Deregulated expression of miR-26a and Ezh2 in rhabdomyosarcoma.
Ciarapica R; Russo G; Verginelli F; Raimondi L; Donfrancesco A; Rota R; Giordano A
Cell Cycle; 2009 Jan; 8(1):172-5. PubMed ID: 19106613
[No Abstract] [Full Text] [Related]
19. Identification of EZH2 as a molecular marker for a precancerous state in morphologically normal breast tissues.
Ding L; Erdmann C; Chinnaiyan AM; Merajver SD; Kleer CG
Cancer Res; 2006 Apr; 66(8):4095-9. PubMed ID: 16618729
[TBL] [Abstract][Full Text] [Related]
20. EZH2 and cancer stem cells: fact or fiction?
Crea F
Epigenomics; 2011 Apr; 3(2):127-8. PubMed ID: 22122274
[No Abstract] [Full Text] [Related]
[Next] [New Search]
